UC-MSC Stem Cell Therapy and Ovarian Reserve: Regenerative Support for Female Fertility Biology

By Napat Aroonpai

For women diagnosed with diminished ovarian reserve (DOR) or premature ovarian insufficiency (POI), the journey through fertility treatments can be emotionally and physically draining. The diagnosis often implies a limited quantity and quality of eggs, narrowing the path to conception. In recent years, regenerative medicine has offered a new avenue of hope.

UC-MSC therapy for ovarian reserve utilizes the potent regenerative capabilities of Mesenchymal Stem Cells derived from the Umbilical Cord (UC-MSCs). This approach does not aim to reverse biological aging or create new eggs, but rather to create a supportive ovarian environment that may maximize the function of existing, dormant follicles.

📌 If you’re interested in why umbilical cord cells are often preferred over bone marrow or fat-derived cells, we have an interesting article that discusses why UC-MSCs are superior to other stem cell sources, which you can read via the internal link.

This guide provides an evidence-based overview of how UC-MSCs support ovarian function, who may benefit, and how this therapy is integrated into modern fertility planning.

Is low ovarian reserve the same as early menopause? No. A low ovarian reserve (DOR) means the number of eggs is lower than expected for a woman’s age, but she may still conceive. Premature Ovarian Insufficiency (POI) involves the loss of function before age 40. Early menopause is the final cessation of menstruation and fertility before age 45, diagnosed retrospectively after 12 months of amenorrhea.

Understanding Ovarian Aging and Reserve

The ovary ages faster than any other organ. A woman’s peak reproductive potential is in her early 20s, with a gradual decline until age 35, after which the decline accelerates.

Ovarian Reserve Markers: What Do They Mean?

Evaluating the ovarian reserve provides insight into the quantity of remaining eggs (oocytes) and helps predict response to ovarian stimulation.

  • Anti-Müllerian Hormone (AMH): Produced by small follicles in the ovaries. AMH levels correlate with the size of the resting follicle pool. Does AMH predict natural fertility? Not reliably. While low AMH indicates a low reserve, it does not guarantee infertility or prevent natural conception, especially in younger women.
  • Follicle-Stimulating Hormone (FSH): Measured on day 3 of the cycle, FSH stimulates follicle growth. High FSH levels often indicate the ovaries are working harder to recruit follicles, suggesting a diminished reserve.
  • Antral Follicle Count (AFC): A transvaginal ultrasound to count the number of small, developing follicles (2-10mm) in both ovaries.

Comparing Ovarian Reserve Conditions

ConditionDefinitionKey CharacteristicsTypical Age
Diminished Ovarian Reserve (DOR)Reduction in egg quantity/quality due to age or other factors.Lower AMH, higher FSH, lower AFC. Conception is still possible but may require assistance.>35 (can be younger)
Premature Ovarian Insufficiency (POI)Loss of ovarian function before age 40.Irregular cycles, low estrogen, high FSH. Formerly known as premature ovarian failure.
Age-Related Ovarian SenescenceNatural decline in reserve and quality due to chronological aging.Gradual decline in all markers.35+

How UC-MSC Therapy Supports Ovarian Function

When utilizing umbilical cord mesenchymal stem cells for ovarian reserve, the therapeutic goal is regenerative support, not reversal of oogenesis.

The ovarian microenvironment degrades with age due to factors like chronic inflammation, oxidative stress, and vascular insufficiency. UC-MSCs act as “biologics” that home in on damaged tissues and secrete a potent cocktail of bioactive molecules.

📌 If you’re interested in how MSCs calm overactive immune cells throughout the body, we have an interesting article that discusses mesenchymal stem cell therapy for immune modulation, which you can read via the internal link.

Key Biological Mechanisms (Regenerative Support)

The primary mechanism is paracrine signaling (cell-to-cell communication):

  • Anti-Inflammatory Effects: MSCs modulate the immune environment, reducing local inflammation that contributes to follicle atresia (cell death).
  • Reduction of Fibrosis: They help decrease scar-like tissue formation in the aging ovary.
  • Angiogenesis: MSCs promote the formation of new blood vessels (neovascularization), improving blood flow and oxygenation to the ovarian cortex.
  • Anti-Apoptotic Action: They release factors that protect existing follicles from programmed cell death.
  • Mitochondrial Transfer: Emerging evidence suggests MSCs may transfer healthy mitochondria to damaged oocytes, potentially improving egg quality.

To understand the specific molecular pathways, read our detailed article on [Ovarian Rejuvenation Mechanisms].

Candidacy: Who Can Benefit?

UC-MSC therapy is generally considered for women who have not responded well to conventional treatments or who wish to improve their ovarian environment prior to IVF.

Ideal Candidates Include:

  • Women under 40 with Premature Ovarian Insufficiency (POI).
  • Women with Diminished Ovarian Reserve (DOR) indicated by low AMH and high FSH for their age.
  • “Poor Responders” to IVF stimulation protocols.
  • Women experiencing perimenopausal symptoms who wish to restore hormonal balance.

Important Considerations:

  • Does UC-MSC therapy work if no follicles are left? No. If the ovary is completely depleted of follicles (menopause), stem cells cannot create new eggs. A thorough AFC scan is required to determine candidacy.
  • It is important to note that stem cell therapy for ovarian reserve is an innovative approach and has not been approved by the FDA for infertility treatment. It remains under active clinical investigation.

The Clinical Evidence: UC-MSC Therapy for POI

Research into UC-MSC for premature ovarian insufficiency has shown promise in both preclinical models and early human clinical trials. Studies indicate that UC-MSC transplantation can potentially restore menstrual cycles, lower FSH levels, and increase AMH levels in some patients with POI.

For example, a Phase I/II clinical trial (e.g., NCT02696899) investigated the safety and efficacy of umbilical cord-derived MSC transplantation in patients with POI, reporting improvements in hormonal profiles and, in some cases, spontaneous pregnancies.

To review the data relevant to your situation, see [Clinical Outcomes of Ovarian Rejuvenation].

The Vega Treatment Protocol: Safety and Quality

At Vega Stem Cell, patient safety and cellular efficacy are paramount. We adhere to strict international standards for laboratory processing and clinical administration.

📌 If you’re planning treatment in Thailand and want a practical checklist for choosing a safe clinic, we have an interesting article that discusses whether stem cell therapy is safe in Thailand, which you can read via the internal link.

How to Check UC-MSC Quality

Before any fertility treatment, it is essential to verify the quality of the stem cells. Vega’s laboratory follows GMP (Good Manufacturing Practice) standards:

  • Source: Ethically donated, screened human umbilical cords (Wharton’s jelly).
  • Sterility Testing: Rigorous testing for bacteria, fungi, mycoplasma, and endotoxins.

Administration Method and Dosage

The method of delivery is crucial for efficacy. Vega specialists utilize intraovarian injection via ultrasound guidance,similar to an egg retrieval procedure. This ensures the cells are delivered directly into the ovarian cortex where they are needed most.

  • Dosage: The typical dosage involves a concentration of 5 to 10 million UC-MSCs per ovary, suspended in a physiological solution. In some cases, a combined approach of intraovarian injection plus IV infusion is used to address systemic inflammation.

Post-Treatment Timeline and Follow-Up

Regenerative processes take time. Patients are monitored through a specific follow-up timeline:

  • 1-3 Months: Initial assessment of menstrual cycle regularity and menopausal symptoms.
  • 3-6 Months: Recommended window for retesting hormonal markers (AMH, FSH) and AFC via ultrasound.
  • 3-12 Months: The primary period during which spontaneous conception or improved IVF response may occur.

UC-MSC Therapy and IVF Planning

UC-MSC therapy is frequently used as a priming step before an IVF cycle.

Integrating with IVF: Many specialists recommend undergoing UC-MSC therapy 3 to 6 months before beginning an IVF stimulation protocol. The goal is to optimize the ovarian environment, potentially increasing the number of retrieved eggs and improving embryo quality during the subsequent cycle.

Can UC-MSC therapy replace IVF?

For women with severe DOR or POI, UC-MSC therapy is not a guarantee of natural pregnancy and generally cannot fully “replace” IVF if significant male factor infertility or tubal issues exist.However, it may help patients utilize their own eggs rather than donor eggs by improving the ovarian reserve markers and response to stimulation.

Conclusion

UC-MSC therapy represents a significant advancement in regenerative support for female fertility, offering new hope for women with low ovarian reserve or POI. While it is not a cure for menopause or a guarantee of pregnancy, it provides a biological method to potentially revitalize existing ovarian function.

Next Steps If you are considering UC-MSC therapy, an individual assessment is necessary. Please fill out our confidential consultation form below.

(Note: In your current form, the default condition is set to “Anti Aging”. Please ensure you select “Fertility / Ovarian Rejuvenation” from the menu so your inquiry is directed to our reproductive specialists.)

References:

  • He, X., et al. (2018). Umbilical cord mesenchymal stem cell transplantation for premature ovarian insufficiency: A randomized controlled trial. Stem Cell Research & Therapy.
  • ClinicalTrials.gov. (n.d.). Mesenchymal Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF). Identifier: NCT02696899. (Example of a clinical trial name).

Disclaimer: The information provided is for educational purposes only and does not constitute medical advice. Please consult with a qualified reproductive endocrinologist regarding your specific fertility diagnosis and treatment options.

For more information

you can reach me directly on WhatsApp or Email

Here’s our official link

This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.

Accept All Accept Required Only